Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Crinetics Pharmaceuticals Inc (CRNX) USD0.001

Sell:$17.88 Buy:$17.95 Change: $0.39 (2.22%)
Market closed |  Prices as at close on 5 August 2021 | Switch to live prices |
Sell:$17.88
Buy:$17.95
Change: $0.39 (2.22%)
Market closed |  Prices as at close on 5 August 2021 | Switch to live prices |
Sell:$17.88
Buy:$17.95
Change: $0.39 (2.22%)
Market closed |  Prices as at close on 5 August 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Crinetics Pharmaceuticals, Inc. is a United States-based therapeutics company. The Company is focused on discovery, development, and commercialization of oral nonpeptide therapeutics for endocrine diseases and endocrine-related tumors. It uses a pipeline of oral nonpeptide (small molecule) new chemical entities that targets peptide G protein coupled receptors (GPCRs) to treat a variety of endocrine diseases. The Company's product range includes CRN00808, for the treatment of acromegaly; CRN02481, for the treatment of hyperinsulinemias; CRN01941, for the treatment of neuroendocrine tumors (NETs).

Contact details

Address:
10222 Barnes Canyon Rd Bldg 2
SAN DIEGO
92121-2711
United States
Telephone:
+1 (858) 4506464
Website:
https://www.crinetics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CRNX
ISIN:
US22663K1079
Market cap:
$665.78 million
Shares in issue:
37.59 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • R. Scott Struthers
    President, Chief Executive Officer, Co-Founder, Director
  • Marc Wilson
    Chief Financial Officer
  • Garlan Adams
    General Counsel
  • Alan Krasner
    Chief Medical Officer
  • Ajay Madan
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.